Table 1.
Patient Characteristics
| ALL PATIENTS (n=859) | Caucasian (n=697) | AA (n=162) | p-value |
|---|---|---|---|
| Age (years), median | 59 | 54 | 0.037 |
| Interquartile Range (years) | 49-67 | 47-67 | |
| Clinical subtype, n (%) | 1.81e-07 | ||
| ER+ | 458 (65.7%) | 82 (50.6%) | 4.21e-04 |
| HER2+ | 125 (17.9%) | 22 (13.6%) | 0.204 |
| ER-/HER2- (TNBC) | 114 (16.4%) | 58 (35.8%) | 1.78e-07 |
| Stage, n (%) | 0.379 | ||
| I | 131 (18.8%) | 30 (18.5%) | |
| II | 382 (54.8%) | 93 (57.4%) | |
| III | 163 (23.4%) | 30 (18.5%) | |
| IV | 11(1.6%) | 4 (2.5%) | |
| Not available | 10 (1.4%) | 5 (3.1%) | |
| TNBC ONLY (n=172) | Caucasian (n=114) | AA (n=58) | p-value |
| Age (years), median | 54.5 | 51.5 | 0.839 |
| Interquartile Range (years) | 48-62 | 47-66 | |
| Stage | 0.788 | ||
| I | 22 (19.3%) | 10 (17.2%) | |
| II | 70 (61.4%) | 34 (58.6%) | |
| III | 17 (14.9%) | 12 (20.7%) | |
| IV | 2 (1.8%) | 0 (0%) | |
| Not available | 3 (2.6%) | 2 (3.5%) |
Abbreviations: ER = Estrogen Receptor, HER2 = Human Epidermal Growth Factor Receptor-2, TNBC = Triple-Negative Breast Cancer